Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Spyre Therapeutics, Inc. (SYRE) had Weighted-Average Shares Outstanding (Diluted) of 60.33M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-36.72M |
|
-- |
|
-- |
|
$41.94M |
|
$-41.94M |
|
$5.22M |
|
$-36.72M |
|
$-36.72M |
|
$-36.72M |
|
$-36.72M |
|
$-36.72M |
|
$-36.72M |
|
$-41.94M |
|
$-41.94M |
|
60.33M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
60.33M |
$-0.49 |
|
$-0.49 |
|
| Balance Sheet Financials | |
$538.83M |
|
-- |
|
-- |
|
$538.83M |
|
$83.06M |
|
-- |
|
-- |
|
$83.06M |
|
$299.95M |
|
$455.77M |
|
$455.77M |
|
60.37M |
|
| Cash Flow Statement Financials | |
$-87.56M |
|
$78.94M |
|
$0.86M |
|
$89.42M |
|
$81.66M |
|
$-7.76M |
|
$18.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.49 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-87.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.24% |
|
-8.06% |
|
-6.81% |
|
-8.06% |
|
$7.55 |
|
$-1.45 |
|
$-1.45 |
|